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Abstract
Background: Chronic anticoagulation is a standard of care in idiopathic pulmonary arterial hypertension (IPAH).
However, hemostatic abnormalities in this disease remain poorly understood. Therefore, we aimed to study markers
of thrombogenesis and fibrinolysis in patients with IPAH.
Methods: We studied 27 consecutive patients (67% female) with IPAH aged 50.0 years (IQR: 41.0 - 65.0) and 16
controls without pulmonary hypertension. Prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin (TAT)
complexes were measured to assess thrombogenesis; tissue-type plasminogen activator (tPA) antigen and plasmin-
anti-plasmin complex to characterize activation of fibrinolysis; plasminogen activator inhibitor 1 (PAI-1) to measure
inhibition of fibrinolysis; and endothelin-1 (ET-1) and interleukin-6 (IL-6) to assess endothelial activation and systemic
inflammation, respectively. In addition, in treatment-naive IPAH patients these markers were assessed after 3 months
of PAH-specific therapies.
Results: TPA (10.1[6.8-15.8] vs 5.2[3.3-7.3] ng/ml, p<0.001), plasmin-anti-plasmin (91.5[60.3-94.2] vs
55.8[51.1-64.9] ng/ml, p<0.001), IL-6 (4.9[2.5-7.9] vs 2.1[1.3-3.8] pg/ml, p=0.001) and ET-1 (3.7 [3.3-4.5] vs
3.4[3.1-3.5], p= 0.03) were higher in patients with IPAH than in controls. In IPAH patients plasmin-anti-plasmin and
tPA correlated positively with IL-6 (r=0.39, p=0.04 and r=0.63, p<0.001, respectively) and ET-1 (r=0.55, p=0.003 and
r=0.59, p=0.001, respectively). No correlation was found between tPA or plasmin-anti-plasmin and markers of
thrombogenesis. Plasmin-anti-plasmin decreased after 3 months of PAH specific therapy while the other markers
remained unchanged.
Conclusions: In the present study we showed that markers of fibrynolysis were elevated in patients with IPAH
however we did not find a clear evidence for increased thrombogenesis in this group of patients. Fibrinolysis,
inflammation, and endothelial activation were closely interrelated in IPAH.
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Introduction
Histopathological studies have shown a high prevalence of in
situ thrombosis in patients with idiopathic pulmonary arterial
hypertension (IPAH) [1,2]. Additionally, some observational
studies suggested a survival benefit in patients with IPAH when
taking oral anticoagulation [3]. Therefore, the use of vitamin K
antagonists (VKA) has become a standard of care in IPAH [4].
This indication, however, has been questioned recently with
the introduction of advanced PAH specific therapy which
relieved many patients from bed resting [5,6]. Additionally,
recent data suggested an increased bleeding risk in patients
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with IPAH compared to patients taking VKA for other reasons
[7].
Generally, increased thrombotic or bleeding risk might stem
from an altered balance between procoagulant, anticoagulant
and fibrinolytic activity. The thrombin mediated enzymatic
conversion of fibrinogen to fibrin is the major step in clot
formation. Typically, in response to the generation of fibrin
thrombus in vivo there is an activation of the fibrinolytic system
[8]. Currently, the characteristics of these two counteracting
processes in IPAH are poorly known.
Therefore, we aimed to characterize the process of
thrombogenesis and fibrinolysis activation in patients with
IPAH. As thrombogenesis and fibrinolysis in systemic
circulation are interrelated with inflammation and endothelial
function we also measured markers of inflammation and
endothelial activation.
Methods
Study population
All study participants were recruited consecutively at the
Department of Cardiac and Vascular Diseases at John Paul II
Hospital in Krakow, Poland between July 2009 and November
2012 as shown in Figure 1.
Eligible patients were 1) patients with known IPAH scheduled
for routine follow-up visit and 2) patients with suspected IPAH
referred for diagnosis and management at our pulmonary
hypertension (PH) centre. The latter group consisted of all
patients, irrespectively of symptoms, in whom
echocardiography showed increased right ventricular systolic
pressure >40 mmHg [9] and in whom right heart catheterization
was made in order to confirm or exclude the diagnosis of
pulmonary hypertension. To be included in the study group
secondary aetiologies of PH (liver disease, HIV infection,
connective tissue disease, congenital heart defect, left heart
disease, chronic thromboembolic disease and lung diseases)
had to be excluded. Additional exclusion criteria were age ≤ 18
years, acute infection or apparent inflammatory process.
Patients with mean pulmonary artery pressure (mPAP)
≥25mmHg and pulmonary artery wedge pressure (PAWP) ≤15
mmHg were diagnosed as IPAH. Patients with mPAP < 25
mmHg, PAWP ≤15mmHg, and a cardiac index (CI) ≥ 2.5
L/min/m2 were taken as controls. We considered the result of
echocardiography (RVSP >40 mmHg) in the latter group as
false positive. The institutional ethics committee (Komisja
Bioetyczna przy Okręgowej Izbie Lekarskiej w Krakowie)
approved the study protocol, and written informed consent was
obtained from each patient before starting the study. All clinical
investigations have been conducted according to the principles
expressed in the Declaration of Helsinki.
Study protocol
Data on medical history, physical examination and laboratory
parameters were obtained before cardiac catheterization.
Patients with newly diagnosed IPAH were invited for a follow-
up examination 3 months after initiation of PAH specific
therapy. Cardiovascular risk factors were assessed according
to current guidelines[10-14]. A smoker was defined as having
smoked at least for one month during the previous 12 months;
all others were classified as non-smokers. Body mass index
was calculated as mass[kg]/height[m]2. Coronary angiography
was performed in each patient to screen for coronary artery
disease.
Cardiac catheterisation
Right heart catheterization (RHC) was performed in supine
position from the right femoral vein access using a Swan-Ganz
catheter in every patient. The acquisition of pressure waves
was made at end expiration. Cardiac output was measured
using the Fick oxygen consumption method. Blood oxygen
saturation was measured with Co-oximeter OSM3
(Radiometer, Copenhagen, Denmark) while the oxygen
consumption was estimated from the LaFarge equation as
previously described [15]. Pulmonary vascular resistance was
calculated as the difference between mPAP and PAWP divided
by cardiac output.
Measurement of laboratory parameters
The venous blood samples were taken from each patient
after an overnight fast in the morning on the day of
catheterization. Additionally, in patients with newly diagnosed
IPAH, repeat venous blood samples were taken three months
after initiation of PAH specific therapy. Patients who were
previously treated with VKA (only patients with prior diagnosis
of IPAH) were switched to enoxaparine at least three days
before RHC and had to have an INR < 1.2 when the blood was
taken for further analysis. Patients did not receive enoxaparine
in the morning of the day when blood samples were taken for
analysis.
Blood samples were taken from the antecubital vein using
sodium citrate (0,109 M) or EDTA as anti-coagulants as
recommended by the manufacturer’s instructions for the
assays and centrifuged within one hour after collection (2500 g,
20 min). Following the current recommendations [16] the
second tube was used for the coagulation specimen. Plasma
samples were stored in aliquots at −80°C. Immunoassays were
performed according to manufacturers’ instructions.
Prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin
(TAT) complexes were measured to assess thrombogenesis.
Tissue-type plasminogen activator (tPA) antigen and plasmin-
anti-plasmin complex were measured to characterize activation
of fibrinolysis. D-Dimer was chosen to reflect both processes.
Plasminogen activator inhibitor 1 (PAI-1) was measured to
assess inhibition of fibrinolysis. Endothelin-1 (ET-1) was used
as a marker of endothelial activation, and interleukin-6 (IL-6) as
a marker of chronic systemic inflammation.
F1+2 was assessed in citrate plasma with ELISA kit Human
Prothrombin Fragment 1+2 (F1+2) (USCN Life Science Inc,
TX, USA). TAT complexes concentrations were determined in
citrate plasma by means of ELISA assay IMUBIND TAT ELISA
(American diagnostica GmbH, Pfungstadt, Germany). TPA
antigen levels were measured in citrate plasma by means of a
one-step two-site immuno-assay Zymutest tPA antigen
(BioMed, Neuville-sur-Oise, France). Plasmin-anti-plasmin
complex concentrations were determined in citrate plasma by
means of ELISA assay Plasmin-anti-plasmin Assay Kit (USCN
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Figure 1.  Study flow chart explaining selection of participants of the study and depicting the follow-up scenario.  CI,
cardiac index; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery
wedge pressure.
doi: 10.1371/journal.pone.0082628.g001
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Life Science Inc; Wuang, China). D-dimer levels were
measured in citrate plasma by means of ELISA Zymutest D-
dimer (Hyphen BioMed, Neuville-sur-Oise, France). PAI-1
levels were measured in citrate plasma by means of a one-step
two-site immuno-assay Zymutest PAI-1 activity (Hyphen
BioMed, Neuville-sur-Oise, France). The concentration of ET-1
was assessed in EDTA plasma by means of ELISA assay
Human Endothelin-1 Quantikine (R&D Systems, MN, USA).
The concentration of IL-6 was assessed in EDTA plasma by
means of ELISA assay Human IL-6 Quantikine HS (R&D
Systems, MN, USA).
Statistical analysis
Continuous variables were reported using median and
interquartile range, categorical variables were described as
counts and percentages. Patients with IPAH and controls were
compared with the Mann Whitney U-test for the continuous
variables and with the chi square test for categorical variables.
The Wilcoxon rank sum test was used to compare parameters
at baseline and after three months of treatment. Spearman
rank correlation was used to assess the association between
continuous variables. The significance level was set at p <
0.05. Statistical analysis was performed with Statistica PL
software [StatSoft, Inc. (2010). STATISTICA (data analysis
software system), version 9.1. Tulsa, USA www.statsoft.com]
and MedCalc version 11.6.1.0 (MedCalc Software, Mariakerke,
Belgium).
Results
Baseline characteristics
Among 234 patients who were assessed for eligibility (Figure
1), 191 patients were excluded due to other aetiologies of
pulmonary hypertension (n=175), lack of informed consent
(n=4), and missing hemodynamic criteria (n=12). The study
population consisted of 43 participants: 27 patients with IPAH
and 16 controls.
No differences in age and sex were found between patients
and controls. At baseline, the majority of patients (n = 21; 78%)
were treatment naive; the others were treated with sildenafil (2
patients), sildenafil and inhaled iloprost (1 patient), inhaled
iloprost (1 patient), treprostinil s.c. with sildenafil (1 patient),
and sitaxsentan (1 patient). After confirming the diagnosis of
IPAH all drug-naive patients received PAH specific drugs:
Fifteen patients were prescribed sildenafil, 2 verapamil, 1
inhaled iloprost, 1 sildenafil + inhaled iloprost and 2
subcutaneous treprostinil. Patient characteristics involving
cardiovascular risk factors, cardiovascular drugs used before
study enrolment and hemodynamic data are presented in Table
1. Seventeen (63%) IPAH patients were in WHO functional
class III, 8 patients in functional class II and 2 patients in class
IV at study entry. All but one IPAH patients and all controls had
normal coronary arteries.
Twenty-one patients who were treatment naive at
recruitment received PAH specific drug treatment after baseline
measurements and were followed for 3 months. In 17 of these
21 patients we were able to reassess the laboratory markers
after 3 months. From the remaining 4 patients 2 patients died
during the follow up period, and 2 patients did not appear at the
3-months follow-up visit (Figure 1).
Markers of haemostasis, inflammation and endothelial
dysfunction
Both markers of fibrinolysis, tPA and plasmin-anti-plasmin,
were significantly higher in patients with IPAH than in controls
(Table 2, Figure 2). In contrast, markers of thrombogenesis,
TAT and F1+2, as well as PAI-1 and D-dimer did not differ
between patients with IPAH and controls. IL-6 and ET-1 were
higher in IPAH patients than in controls (Table 2, Figure 2).
Similar results were obtained when only treatment naive IPAH
patients were included in the analysis.
We did not observe a significant effect of previous treatment
with VKA on the markers of thrombogenesis. F1+2 (76.0
Table 1. Patient characteristics.
Variable IPAH (n=27) Controls (n=16) P
Age [years] 50.0 (41.0-65.0) 54.0 (37.0-60.5) 0.76
Sex [males] 9 (33%) 5 (31%) 0.84
BMI [kg/m2] 23.0 (21.0-26.0) 27.3 (22.3-28.3) 0.02
Total cholesterol [mmol/l] 4.1 (3.6-4.7) 4.7 (4.6-5.3) 0.007
LDL-cholesterol [mmol/l] 2.4 (1.7-2.8) 2.7 (2.5-3.5) 0.03
HDL-cholesterol [mmol/l] 1.3 (1.1-1.5) 1.6 (1.3-1.8) 0.01
Triglycerides [mmol/l] 1.0 (0.8-1.4) 1.1 (0.9-1.4) 0.7
Diabetes 4 (15%) 0 0.28
Systemic arterial
hypertension
10 (37%) 8 (50%) 0.61
Smoking 0 0 -
hsCRP [mg/dl] 2.4 (1.2-8.2) 1.1 (0.7-2.2) 0.004
Creatinine [umol/l] 80.0 (73.0-98.0) 68.5 (59.0-88.5) 0.02
Drugs taken before entering
the study
   
Statins 9 (33%) 6 (38%) 0.96
Diuretics 12 (44%) 0 0.005
ACEI 6 (22%) 6 (38%) 0.47
Beta blockers 8 (30%) 6 (38%) 0.80
CCB 8 (30%) 2 (12.5%) 0.36
Vitamin K antagonist* 6 0 -
Hemodynamic data    
PA mean pressure [mmHg] 54.0 (44.3-66.3) 11.0 (9.5-13.0) <0.001
RA pressure [mmHg] 8.0 (5.0-13.0) 2.0 (2.0-3.0) <0.001
PAW mean pressure
[mmHg]
8.0 (4.5-11.3) 7.5 (5.5-9.0) 0.36
Ao mean pressure [mmHg] 90.0 (79.0-96.8) 100.0 (94.0-102.0) 0.02
Cardiac index [l/min/m2] 1.6 (1.4-1.9) 2.7 (2.7-2.8) <0.001
Estimated oxygen
consumption (ml/min)
187.5 (176.2-203.1)
180.6 ( 160.9 -
270.6)
0.58
PVR [WU] 15.9 (11.3-20.9) 0.7 (0.4-1.3) <0.001
*. only patients with known IPAH were treated with vitamin K antagonists before
enrolment to the study
ACEI - angiotensin converting enzyme inhibitor, BMI - body mass index, CCB -
calcium channel blockers, HDL - high density lipoprotein, LDL - low density
lipoprotein, PA - pulmonary artery, PAW - pulmonary artery wedge, PVR -
pulmonary vascular resistance, RA - right atrium, WU - Wood Units
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Table 2. Markers of hemostasis, Interleukin-6 and
Endothelin-1 in patients with IPAH and controls.
Parameter IPAH (n=27) Controls (n=16) P
tPA [ng/ml] 10.1 (6.8-15.8) 5.2 (3.3-7.3) <0.001
Plasmin-anti-plasmin [ng/ml] 91.5 (60.3-94.2) 55.8 (51.1-64.9) <0.001
TAT (ng/ml) 8.7 (4.5-14.9) 8.2 (4.9-22.2) 0.8
F1+2 (ng/ml) 73.9 (59.7-84.4) 71.8 (63.5-78.9) 0.92
PAI-1 (ng/ml) 0.58 (0.1-1.4) 0.46 (0.2-1.5) 0.94
Fibrinogen (g/l) 3.1 (2.7-3.7) 3.2 (2.8-3.5) 0.86
D-dimer (ng/ml) 342.8 (243.1-648.9) 513.4 (263.5-732.7) 0.56
Il-6 (pg/ml) 4.9 (2.5-7.9) 2.1 (1.3-3.8) 0.001
ET-1 (pg/ml) 3.7 (3.3-4.5) 3.4 (3.1-3.5) 0.03
ET-1 - endothelin-1, F1+2 - prothrombin fragments 1+2, IL-6 - interleukin 6, tPA-
tissue plasminogen activator, PAI-1 - plasminogen activator inhibitor, TAT -
thrombin-anti-thrombin
Table 3. Median change of markers of hemostasis,
Interleukin-6, and Endothelin-1 after 3 months of PAH
specific treatment in patients who were treatment naive at
study entry.
Parameter Median (IQR) P
tPA [ng/ml] 0.01 (-5.1 - 4.9) 0.96
Plasmin-anti-plasmin [ng/ml] -2.9 (-5.6 - -0.2) 0.02
TAT (ng/ml) -0.7 (-5.9 - 12.9) 0.8
F1+2 (ng/ml) 9.0 (-4.2 - 19.5) 0.27
PAI-1 (ng/ml) 0.09 (-0.9 - 0.5) 0.78
D-Dimer (ng/ml) 6.2 (-326.4 - 67.1) 0.46
Il-6 (pg/ml) 0.6 (-2.3 - 3.0) 0.49
ET-1 (pg/ml) -0.2 (-1.0 -0.4) 0.31
ET-1 - endothelin-1, F1+2 - prothrombin fragments 1+2, IL-6 - interleukin 6, IQR -
interquartile range, tPA- tissue plasminogen activator, PAI-1 - plasminogen
activator inhibitor, TAT - thrombin-anti-thrombin
Table 4. Correlations between tPA and plasmin-anti-
plasmin and other haemostatic variables, Endothelin-1 and
Interleukin-6 in patients with IPAH.
 tPA Plasmin-anti-plasmin
 r P r P
     
Plasmin-anti-plasmin [ng/ml] 0.4 0.01 - -
TAT (ng/ml) 0.1 0.64 0.03 0.86
F1+2 (ng/ml) -0.38 0.06 -0.3 0.12
PAI-1 (ng/ml) 0.44 0.03 0.29 0.13
D-Dimer (ng/ml) 0.34 0.09 0.02 0.93
Fibrinogen -0.01 0.68 -0.1 0.64
Il-6 0.63 <0.001 0.39 0.04
ET-1 0.59 0.001 0.55 0.003
ET-1 - endothelin-1, F1+2 - prothrombin fragments 1+2, IL-6 - interleukin 6, tPA-
tissue plasminogen activator, PAI-1 - plasminogen activator inhibitor, TAT -
thrombin-anti-thrombin
[60.2-79.8] vs 73.7 [61.5-85.2], p =0.87) and TAT (8.7
[5.8-13.3] vs 8.4 [3.6-16.4], p=0.82) were similar in IPAH
patients previously treated with VKA and those without prior
VKA intake.
In previously drug-naive IPAH patients we observed a
reduction of plasmin-anti-plasmin levels after 3 months of
treatment with PAH specific drugs, while tPA, D-Dimer, TAT,
F1+2, PAI-1, and IL-6, ET-1 remained unchanged (Table 3,
Figure 3).
Correlations of tPA and plasmin-anti-plasmin in
patients with IPAH
A positive correlation was found between tPA and plasmin-
anti-plasmin and between tPA and PAI-1 (Table 4, Figure 4) in
patients with IPAH. Furthermore, both plasmin-anti-plasmin
and tPA correlated positively with IL-6 and ET-1, respectively
(Table 4, Figure 4). No correlation was found between tPA or
plasmin-anti-plasmin and markers of thrombogenesis (F1+2,
TAT) while a non-significant trend for a positive correlation
between tPA and F1+2 was observed. The analysis made after
exclusion of the already treated IPAH patients confirmed the
observations made on the whole study group. In the control
group we found a positive correlation between tPA and PAI-1
(r=0.59, p=0.01), and fibrinogen (r=0.6, p=0.02), and between
plasmin-anti-plasmin and fibrinogen (r=0.56, p=0.02).
Discussion
In the present study we have shown that markers of
fibrinolysis were elevated in patients with IPAH while markers
of thrombogenesis were not different from controls without PH.
Furthermore, we found significant correlations between
markers of fibrinolysis and both inflammation as well as
endothelial activation indicating that these three distinct
processes are interrelated in IPAH.
Current data on coagulation and the fibrinolytic systems in
IPAH are inconsistent. Increased thrombin activity as
measured by the level of circulating fibrinopeptide A was
shown in one study [17]. However thrombin activity was not
different between IPAH and controls in two other studies in
which F1+2 and TAT were measured [18,19]. These data were
published in 1990s and have not been reproduced in the
modern era of pulmonary hypertension. However the changing
demographics of IPAH population [20] and diagnostic criteria
for this disease [4,21] limit extrapolation of such historical data
to the current patient population.
Plasma markers of fibrinolysis such as tPA and plasmin-anti-
plasmin were similar in PAH and controls in some studies
[18,19] but elevated in other studies in patients with PAH
associated with systemic sclerosis [8] and in women with IPAH
[22]. Discrepant results were also shown for PAI-1 activity
[18,19,23]. In our study, plasma levels of F1+2 and TAT
complexes were similar in patients with IPAH and in controls
suggesting lack of increased thrombin activation. In contrast,
increased levels of tPA and plasmin-anti-plasmin complexes
indicate increased fibrinolytic activity in IPAH. Activation of the
fibrinolytic system – as observed in our study - does not
necessarily contradict the high prevalence of thrombotic lesions
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PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e82628
Figure 2.  Comparison of hemostatic markers, Interleukin-6, and Endothelin-1 between patients with idiopathic arterial
hypertension and controls.  ET-1 - endothelin 1, F1+2 - prothrombin fragments 1+2, IL-6 - Interleukin 6, PAI-1 - plasminogen
activator inhibitor 1, TAT - thrombin-antithrombin, tPA - tissue plasminogen activator. In this box-and-whisker plot, the central box
represents the values from the lower to upper quartile (25 to 75 percentile). The middle line represents the median. A line extends
from the minimum to the maximum value, excluding values that are smaller than the lower quartile minus 1.5 times the interquartile
range, or larger than the upper quartile plus 1.5 times the interquartile range.
doi: 10.1371/journal.pone.0082628.g002
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Figure 3.  Levels of haemostatic variables, Interleukin-6 and Endothelin-1 at baseline and after 3 months of pulmonary
arterial hypertension specific therapy.  ET-1 - endothelin-1, F1+2 - prothrombin fragments 1+2, IL-6 - interleukin 6, PAI-1 -
plasminogen activator inhibitor, TAT - thrombin-anti-thrombin, tPA- tissue plasminogen activator.
doi: 10.1371/journal.pone.0082628.g003
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found in autopsy studies of IPAH patients. A recent study has
described fibrin that was resistant to lysis in patients with PH,
suggesting that activated fibrinolysis might be ineffective to
dissolve thrombi in the pulmonary vasculature [24]. On the
other hand, activation of the fibrinolytic system could enhance
the risk of bleeding. In fact, recent data from patients with PH
treated with VKA demonstrated more major bleeding in IPAH
and PAH associated with connective tissue disease than in
CTEPH patients [7]. The authors of this study also reported a
much higher rate of bleeding in this patient population than in
large cohorts of patients treated with VKA for atrial fibrillation or
venous thromboembolism [7].
Apart from thrombogenesis [25,26], other pathophysiologic
stimuli of fibrinolysis have been described. In particular,
endothelial activation and inflammation have been linked with
haemostatic abnormalities in the systemic circulation
Figure 4.  Significant correlations between hemostatic markers, Endothelin-1, and Interleukin-6.  ET-1 - Endothelin -1, IL-6 -
Interleukin 6, PAI-1 - PAI-1 - plasminogen activator inhibitor 1, tPA - tissue plasminogen activator.
doi: 10.1371/journal.pone.0082628.g004
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[25,27,28]. Importantly, both endothelial activation and chronic
inflammation have also been shown to play a significant role
[29,30] in the development of IPAH.
High levels of the proinflammatory cytokine IL-6 have been
reported in most [31] but not all [32] studies in IPAH. The
increased IL-6 production in IPAH is thought to reflect
enhanced synthesis by both inflammatory and pulmonary
vascular cells [33]. In our study PAH specific therapies did not
change plasma levels of IL-6 which confirmed findings from
previous studies on IL-6 and some other inflammatory markers
[34].
In animal models [35] pre-treatment with IL-6 induced a
threefold increase of a basal tPA in the systemic circulation. In
observational studies in various patient populations including
healthy individuals, patients at high cardiovascular risk as well
as in patients with advanced liver disease [36-39] IL-6 levels
have been shown to correlate with tPA, which supports IL-6
induced endothelial cell activation and subsequent release of
tPA as one of the potential underlying pathways [40]. In
experimental models IL-6 also induced the expression of
plasminogen, which is a substrate for plasmin [41]. Plasmin-
anti-plasmin levels were shown to be increased in patients with
chronic inflammatory disorders such as systemic sclerosis [8],
systemic lupus erythematosus, arthritis and other forms of
collagen diseases [42]. The weak correlation between tPA and
plasmin-anti-plasmin levels in our study suggests that
activation of some tPA independent pathways contributed to
elevation of plasmin-anti-plasmin complex. Accordingly some
authors [43] underscored that not only tPA but also urokinase
type plasminogen activator (u-PA) and factor XII dependent
pathways may play a major role in plasminogen activation in
inflammatory diseases.
Endothelin-1 is a marker of endothelial dysfunction [43,44]
and it has been shown to be involved in a spectrum of
cardiovascular diseases ranging from coronary artery disease
to PH. In our study ET-1 was increased in IPAH patients
compared with controls and correlated positively with tPA and
plasmin-anti-plasmin levels. This finding underscores
endothelial cell activation in IPAH leading not only to the
release of ET-1 but also plasminogen activators such as tPA or
uPA, which further convert plasminogen to plasmin.
Of interest, in contrast to all other investigated markers, we
found that the level of plasmin-anti-plasmin complex decreased
after 3 months of PAH specific therapies. It was previously
shown [45] that long-term prostacyclin infusion normalized
platelet function and levels of endothelium derived clotting
factors (factor VIII and von Willebrand factor). However, to the
best of our knowledge, there are no published data showing
the effects of PAH specific therapy on fibrinolytic markers. As
plasmin-anti-plasmin complexes might reflect endothelial
activation, it might be speculated that a reduction of their level
reflects a beneficial effect of PAH specific therapy. The
pathophysiological meaning and clinical consequence of this
finding cannot be explained from our data and need further
investigation.
Study limitations and strengths
We chose only a limited number of haemostatic markers,
namely tPA, plasmin-anti-plasmin, TAT, F1+2, PAI-1 and D-
Dimers, from a broad variety of potential parameters. The
chosen ones, however, represent critical steps in
thrombogenesis and fibrinolysis, which was our focus of
interest. To evaluate endothelial activation and inflammation
we measured only two markers, ET-1 and IL-6, however both
have a well defined role in the pathogenesis of PH [30,46]. This
study allows no insight into causal relationships between
parameters of the hemostasis, endothelial dysfunction and
inflammation, which would require an experimental approach.
The interruption of VKA before catheterization might have
been too short to fully abolish VKA effects on parameters of
thrombogenesis. However, we did not observe significant
differences of F1.2 and TAT between VKA-treated and VKA–
naive IPAH patients.
In this exploratory study we included a limited number of
patients from one pulmonary hypertension centre. Therefore it
is possible that some relevant associations could have been
missed. Considering the low prevalence of IPAH in population
a multicenter study involving large numbers of patients would
be recommended to strengthen the validity of our results.
Strength of our study is the strictly defined IPAH population
diagnosed according to current recommendations by
international guidelines. Moreover, our data help in the search
for the potential mechanisms underlying the recently observed
increased bleeding risk in patients with IPAH.
Conclusions
In the present study we showed that markers of fibrinolysis
were elevated in patients with IPAH however we did not find a
clear evidence for increased thrombogenesis in this group of
patients. Fibrinolysis, inflammation, and endothelial activation
were closely interrelated in IPAH.
In the light of the increased bleeding risk in IPAH further
large scale studies on the role of the specific abnormalities of
haemostasis in IPAH patients are warranted.
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